2022 World Conference on Lung Cancer (ePosters)-EP08.02-164. The Effect of Metformin on Survival Outcomes of Advanced EGFR-mutant NSCLC Patients Treated with EGFR TKIs in Thailand

EP08.02-164. The Effect of Metformin on Survival Outcomes of Advanced EGFR-mutant NSCLC Patients Treated with EGFR TKIs in Thailand

Back to course

Pdf Summary

A retrospective study conducted in Thailand evaluated the effect of metformin on survival outcomes of advanced non-small-cell lung cancer (NSCLC) patients with epidermal growth factor receptor (EGFR) mutations who were treated with EGFR tyrosine kinase inhibitor (TKI). The study included 177 NSCLC patients with or without type 2 diabetes (T2DM) who received treatment at Phramongkutklao Hospital between 2012 and 2021. The patients were divided into three groups: those without T2DM treated with EGFR TKI alone, those with T2DM treated with EGFR TKI and metformin, and those with T2DM treated with EGFR TKI and another hypoglycemic agent.<br /><br />The study found that the concomitant use of metformin and EGFR TKI was associated with increased overall survival (OS) and progression-free survival (PFS) in advanced EGFR-mutant NSCLC patients with T2DM. The analysis of survival outcomes showed higher 1-year PFS and 1-year OS rates in the group receiving both metformin and EGFR TKI compared to the other groups. Treatment-related adverse events were not significantly different among the three groups, although two patients experienced serious adverse events: one developed drug reaction with eosinophilia and systemic symptoms (DRESS), and the other had EGFR-TKI-induced pneumonitis.<br /><br />This is the first study in Thailand to evaluate the use of metformin in combination with EGFR TKI in NSCLC patients. The findings support the potential synergistic effect of metformin and EGFR TKI on survival outcomes. However, further large-scale clinical studies are needed to confirm these results. Overall, this study provides insight into the potential benefits of combining metformin with EGFR TKI in the treatment of advanced EGFR-mutant NSCLC patients with T2DM.

Asset Subtitle

Siriwimon Saichaemchan

Meta Tag

Speaker Siriwimon Saichaemchan

Topic Metastatic Non-small Cell Lung Cancer - Molecular Targeted Treatments

Keywords

retrospective study

metformin

survival outcomes

NSCLC

EGFR mutations

EGFR TKI

type 2 diabetes

PFS

1-year OS rates

synergistic effect